AstraZeneca touts Movantik data in elderly; Novo weighs Victoza study in fatty liver;

@FiercePharma: Who are the top 10 advertisers in Big Pharma? Find out here. FiercePharmaMarketing feature | Follow @FiercePharma

@CarlyHFierce: No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. More from FiercePharmaMarketing | Follow @CarlyHFierce

> AstraZeneca ($AZN) rolled out new study data showing that elderly patients using its bowel drug Movantik had a similar incidence of side effects as those on placebo or standard care. Report

> Novo Nordisk's ($NVO) diabetes med Victoza showed promise in patients with fatty liver disease, according to recent trial data, so the Danish drugmaker is weighing further study. Report

> China's Shanghai pharma has teamed up with online retailer to offer OTC drugs and other products online. Report

> Boehringer Ingelheim highlighted new data on its lung drug Ofev showing that it's effective and safe beyond 52 weeks of use. Report

Medical Device News

@FierceMedDev: ICYMI: Study: Remote monitoring of cardiac device patients results in better survival, less hospitalization. Article | Follow @FierceMedDev

@VarunSaxena2: The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D. Editor's corner | Follow @VarunSaxena2

@EmilyWFierce: Endo scoops up Par Pharma for $8B to gain ground in injectables. FiercePharma story | Follow @EmilyWFierce

> Tech industry group IEEE releases software security guidelines for medical devices. More

> Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Article

Biotech News

@FierceBiotech: Novo's liraglutide works in diabetes and obesity. How about NASH? Story | Follow @FierceBiotech

@JohnCFierce: $EBIO down 78% -- That's what you call an extinction level event. ELEven | Follow @JohnCFierce

> Boehringer strikes $250M deal for Phase I NASH drug. Story

> Sorrento dives into immuno-oncology under Soon-Shiong's shadow. Article

> A pair of Celgene partners gets on the FDA fast track. Report

Pharma Marketing News

> Diabetes app 'One Drop' drops with digerati backing. Article

> AZ bets big on biologics with $285M Swedish facility. Item

> Sanofi seeks the next Teenage Idol in meningitis vaccine campaign. More

> Can pharma + tech wearables be a match made in patient heaven? Story

> No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. Report

Animal Health News

> Iowa biotech firm set to begin testing vaccine against deadly avian flu. Item

> Phibro records strong sales growth despite industry shift from antibiotics. Report

> ImmuCell enjoys spoils of success as demand for calf protector exceeds supply. More

> Jaguar's delayed and downsized IPO garners muted reception on Wall Street. Story

> FDA warns Lilly to stop marketing antibiotic for weight gain in pigs. Article

Biotech IT News

> GenomeDx shares 7 years of cancer testing data with medical center. Item

> Venter's HLI scoops samples from Cleveland Clinic as data-generating drive continues. More

> Allen Institute advances brain-mapping ambitions with cell-type database. Story

> Regeneron lobbying for its database to be the linchpin of Obama's Precision Medicine program. Article

> AstraZeneca dives into genetics of 80,000 samples in search of CV, diabetes insights. Report

And Finally... A major pharmacy chain in Venezuela has started fingerprinting customers in an attempt to stem the tide of medication shortages. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.